Nicoya Extends Series A Financing With Additional $20M To Meet Demand Of Rapidly Growing Proteomics Industry
Nicoya Extends Series A Financing With Additional $20M To Meet Demand Of Rapidly Growing Proteomics Industry
12/16/21, 2:41 PM
Location
kitchenerIndustry
mobile
Round Type
series a
Nicoya Lifesciences, a global leader in digital proteomics solutions, today announced a $20 million Series A extension led by Whitecap Venture Partners. The round included participation from strategic investor Agilent Technologies, a leading global developer of analytical instrumentation for the life sciences, as well as Export Development Canada, BDC Capital, MaRS IAF, Garage Capital, and others. The funding will fuel Nicoya’s continued development & commercialization of AltoTM, an innovative surface plasmon resonance (SPR) platform that digitalizes label-free protein characterization, and expansion into new international markets.
Company Info
Location
kitchener, ontario, canada
Additional Info
Nicoya is a Canadian life sciences tools company specializing in innovative biosensor technology for the academic, biotechnology and pharmaceutical sectors. In their mission to improve human life, Nicoya provides scientists with user-friendly and integrated solutions that accelerate label-free biomolecular analysis. With their world-class expertise in nanotechnology and microfluidics, Nicoya is now helping hundreds of scientists succeed in over 50 countries. Information about Nicoya can be found at nicoyalife.com, on LinkedIn, Twitter, Facebook, and Instagram.